Paul Armstrong - Edmonton, CA Hal Barron - San Francisco CA, US Silvano Berioli - Perugia, IT Frederique Bigonzi - 1'Hay Les Roses, FR Erich Bluhmki - Schwendi, DE Richard Chin - San Francisco CA, US Christopher Granger - Durham NC, US Frans Werf - Herent, BE
International Classification:
A61K038/17
US Classification:
514/012000
Abstract:
The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g. AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin.
Combination Treatment With T-Pa Variant And Low Molecular Weight Heparin
Paul Armstrong - Edmonton, CA Hal Barron - San Francisco CA, US Silvano Berioli - Perugia, IT Frederique Bigonzi - 1'Hay Les Roses, FR Erich Bluhmki - Schwendi, DE Richard Chin - San Francisco CA, US Christopher Granger - Durham NC, US Frans De Werf - Herent, BE
International Classification:
A61K 38/18 A61K 31/727
US Classification:
514012000, 514056000
Abstract:
The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g., AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin.
Combination Treatment With T-Pa Variant And Low Molecular Weight Heparin
Paul Armstrong - Edmonton, CA Hal Barron - San Francisco CA, US Silvano Berioli - Perugia, IT Frederique Bigonzi - 1'Hay Les Roses, FR Erich Bluhmki - Schwendi, DE Richard Chin - San Francisco CA, US Christopher Granger - Durham NC, US Frans Van De Werf - Herent, BE
International Classification:
A61K 38/49 A61P 9/10 G06Q 50/00
US Classification:
424 9464, 705500
Abstract:
The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g., AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin.
Combination Treatment With T-Pa Variant And Low Molecular Weight Heparin
Paul ARMSTRONG - Edmonton, CA Hal BARRON - San Francisco CA, US Silvano BERIOLI - Perugia, IT Frederique BIGONZI - 1'Hay les Roses, FR Erich BLUHMKI - Schwendi, DE Richard CHIN - San Francisco CA, US Christopher GRANGER - Durham NC, US Frans VAN DE WERF - Herent, BE
International Classification:
A61K 38/48 A61P 9/10 A61P 7/04 G06Q 90/00
US Classification:
424 9464, 705500
Abstract:
The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g., AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin.
Dr. Granger graduated from the University of Connecticut School of Medicine in 1984. He works in Durham, NC and 1 other location and specializes in Cardiovascular Disease. Dr. Granger is affiliated with Duke University Hospital and Durham VA Medical Center.
"I've been unconvinced" of the drugs' benefits but now may prescribe them for certain very high risk patients, said Duke University cardiologist Dr. Christopher Granger. But preventing fewer than one heart problem a year at the drug's current price is not cost-effective, he said.
Date: Mar 10, 2018
Category: Health
Source: Google
Device May Benefit Patients with Refractory Angina
It's been estimated that refractory angina affects up to two million people in the United States, according to Christopher Granger, M.D., director of the Cardiac Care Unit at Duke University Medical Center in Durham, N.C., who cowrote an editorial published with the study. Still, larger and longer-t
Date: Feb 05, 2015
Category: Health
Source: Google
Experimental blood flow 'reducer' provides relief for some angina patients
Christopher Granger of the Duke Clinical Research Institute in Durham, North Carolina, and Bernard Gersh of the Mayo Clinic in Rochester, Minnesota, said that if the results are confirmed in larger trials, the technique "may be a welcome and needed addition to the options to improve the quality of
Date: Feb 05, 2015
Category: Health
Source: Google
Novel Device Offers Hope For Heart Patients With No Alternatives
Inan accompanying editorial, Christopher Granger and Bernard Gershwrite that the study was well performed and showed significant improvements in reducing angina and improving quality of life. Its chief limitation are its small size and the possibility that patients or physicians may have become
4) inhibitors] might actually reduce cardiovascular events because they reduce some of the risk factors. But at least we know from these trials that these drugs are safe," Christopher Granger, MD, director of the cardiac care unit at Duke University and not involved in the study, told MedPage Today.
Date: Sep 03, 2013
Category: Health
Source: Google
PhII flop clouds future of Amgen, Cytokinetics heart failure drug
Both Reuters and Bloomberg turned to Duke's heart expert Dr. Christopher Granger, who was not involved in the study, for a response. He made it clear that the data leave this therapy under a cloud for now. "I would be discouraged by this in terms of the implications for the drug having an important
Date: Sep 03, 2013
Category: Health
Source: Google
Study Finds 10% of PCI Patients Readmitted to Hospital Within 30 Days
In an invited commentary, Adrian Hernandez and Christopher Granger write that readmission rates may not be closely linked to overall quality. The increase in one year mortality in readmitted patients may simply mean that patients who are readmitted are sicker and more likely to die. They questio
"We are delighted with these results," said Christopher Granger, a researcher at Duke University's Duke Clinical Research Institute and lead investigator of the study. The results "have profound implications for the opportunity to improve care for patients with atrial fibrillation."